AAAAAA
Results:
1-25
|
Results: 25
Authors:
Guichard, S
Montazeri, A
Chatelut, E
Hennebelle, I
Bugat, R
Canal, P
Citation: S. Guichard et al., Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: Pharmacokinetic and pharmacodynamic evaluation, CLIN CANC R, 7(10), 2001, pp. 3222-3228
Authors:
Guichard, S
Arnould, S
Hennebelle, I
Bugat, R
Canal, P
Citation: S. Guichard et al., Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo, ANTI-CANC D, 12(9), 2001, pp. 741-751
Authors:
Patoux, A
Bleyzac, N
Boddy, AV
Doz, F
Rubie, H
Bastian, G
Maire, P
Canal, P
Chatelut, E
Citation: A. Patoux et al., Comparison of nonlinear mixed-effect and non-parametric expectation maximisation modelling for Bayesian estimation of carboplatin clearance in children, EUR J CL PH, 57(4), 2001, pp. 297-303
Authors:
Guichard, S
Canal, P
Citation: S. Guichard et P. Canal, New techniques and methods in cancer chemotherapy, B CANCER, 88(1), 2001, pp. 85-89
Authors:
Chatelut, E
Pivot, X
Otto, J
Chevreau, C
Thyss, A
Renee, N
Milano, G
Canal, P
Citation: E. Chatelut et al., A limited sampling strategy for determining carboplatin AUC and monitoringdrug dosage, EUR J CANC, 36(2), 2000, pp. 264-269
Authors:
Hennebelle, I
Terret, C
Chatelut, E
Bugat, R
Canal, P
Guichard, S
Citation: I. Hennebelle et al., Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitra-phenylacetate converting carboxylesterase activity, ANTI-CANC D, 11(6), 2000, pp. 465-470
Authors:
Solary, E
Mannone, L
Moreau, D
Caillot, D
Casasnovas, RO
Guy, H
Grandjean, M
Wolf, JE
Andre, F
Fenaux, P
Canal, P
Chauffert, B
Wotawa, A
Bayssas, M
Gennes, P
Citation: E. Solary et al., Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes, LEUKEMIA, 14(12), 2000, pp. 2085-2094
Authors:
Fournet, A
Gilard, V
Malet-Martino, M
Martino, R
Canal, P
De Forni, M
Citation: A. Fournet et al., Stability of commercial solutions of 5-fluorouracil for continuous infusion in an ambulatory pump, CANC CHEMOT, 46(6), 2000, pp. 501-506
Authors:
Montazeri, A
Boucaud, M
Lokiec, F
Pinguet, F
Culine, S
Deporte-Fety, R
Albin, N
Laguerre, B
Goupil, A
Bugat, R
Canal, P
Chatelut, E
Citation: A. Montazeri et al., Population pharmacokinetics of topotecan: intraindividual variability in total drug, CANC CHEMOT, 46(5), 2000, pp. 375-381
Authors:
Guimbaud, R
Guichard, S
Dusseau, C
Bertrand, V
Aparicio, T
Lochon, I
Chatelut, E
Couturier, D
Bugat, R
Chaussade, S
Canal, P
Citation: R. Guimbaud et al., Dihydropyrimidine dehydrogenase activity in normal, inflammatory and tumour tissues of colon and liver in humans, CANC CHEMOT, 45(6), 2000, pp. 477-482
Authors:
Canal, P
Kowalkowski, J
Maeshima, K
Yu, J
Wenzel, H
Snow, J
Arisawa, T
Ikado, K
Shimojima, M
Veramendi, G
Citation: P. Canal et al., Online monitoring in the upcoming Fermilab Tevatron runII, IEEE NUCL S, 47(2), 2000, pp. 240-243
Authors:
Terret, C
Erdociain, E
Guimbaud, R
Boisdron-Celle, M
McLeod, HL
Fety-Deporte, R
Lafont, T
Gamelin, E
Bugat, R
Canal, P
Chatelut, E
Citation: C. Terret et al., Dose and time dependencies of 5-fluorouracil pharmacokinetics, CLIN PHARM, 68(3), 2000, pp. 270-279
Authors:
Chatelut, E
Canal, P
Bugat, R
Citation: E. Chatelut et al., Pharmacokinetics and dose adjustment of carboplatin, B CANCER, 87, 2000, pp. 17-23
Authors:
Simeon, N
Chatelut, E
Canal, P
Nertz, M
Couderc, F
Citation: N. Simeon et al., Anthracycline analysis by capillary electrophoresis - Application to the analysis of daunorubicine in Kaposi sarcoma tumor, J CHROMAT A, 853(1-2), 1999, pp. 449-454
Authors:
Canal, P
Citation: P. Canal, Photosynthesis and 'inverse respiration' in plants: an inevitable misconception?, INT J SCI E, 21(4), 1999, pp. 363-371
Authors:
Perdaems, N
Caunes, N
Canal, P
Chatelut, E
Citation: N. Perdaems et al., Possible excretion at etoposide via the intestinal mucosa, CANC CHEMOT, 43(6), 1999, pp. 520-521
Authors:
Tranchand, B
Amsellem, C
Chatelut, E
Freyer, G
Iliadis, A
Ligneau, B
Trillet-Lenoir, V
Canal, P
Lochon, I
Ardiet, CJ
Citation: B. Tranchand et al., A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients, CANC CHEMOT, 43(4), 1999, pp. 316-322
Authors:
Chatelut, E
Rostaing, L
Gregoire, N
Payen, JL
Pujol, A
Izopet, J
Houin, G
Canal, P
Citation: E. Chatelut et al., A pharmacokinetic model for alpha interferon administered subcutaneously, BR J CL PH, 47(4), 1999, pp. 365-371
Authors:
Gladieff, L
Chatelut, E
Gaspard, MH
Skaf, R
de Forni, M
Mihura, J
Canal, P
Bugat, R
Citation: L. Gladieff et al., Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study, B CANCER, 86(7-8), 1999, pp. 673-677
Authors:
Canal, P
Gautie, L
Gregoire, N
Perdaems, N
Chatelut, E
Citation: P. Canal et al., News on the pharmacokinetics of anticancer drags, B CANCER, 86(1), 1999, pp. 85-89
Authors:
Guichard, S
Terret, C
Hennebelle, I
Lochon, I
Chevreau, P
Fretigny, E
Selves, J
Chatelut, E
Bugat, R
Canal, P
Citation: S. Guichard et al., CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues, BR J CANC, 80(3-4), 1999, pp. 364-370
Authors:
Perdaems, N
Bachaud, JM
Rouzaud, P
Murris-Espin, M
Hermant, C
Mihura, J
Lochon, I
Houin, G
Canal, P
Chatelut, E
Citation: N. Perdaems et al., Relation between unbound plasma concentrations and toxicity in a prolongedoral etoposide schedule, EUR J CL PH, 54(9-10), 1998, pp. 677-683
Authors:
Canal, P
Chatelut, E
Guichard, S
Citation: P. Canal et al., Practical treatment guide for dose individualisation in cancer chemotherapy, DRUGS, 56(6), 1998, pp. 1019-1038
Authors:
Chabot, GG
Robert, J
Lokiec, F
Canal, P
Citation: Gg. Chabot et al., Irinotecan pharmacokinetics, B CANCER, 1998, pp. 11-20
Authors:
Gautie, L
Canal, P
Menguy, A
Latour, JF
Benard, I
Courbard, M
Brunelle, P
Carpentier, Y
Pinguet, F
Chevrier, R
Doly, M
Watelet, M
Briere, M
Viau, P
Duban, M
German, O
Gosselin, P
de La Jarrige, PL
Bertrand, C
Pommier, M
Prebay, D
Citation: L. Gautie et al., Analysis of medical prescription of granulocyte-colony stimulating factorsin 19 French anticancer centers, B CANCER, 85(12), 1998, pp. 1043-1048
Risultati:
1-25
|